Experiences and perspectives on the GIST patient journey

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 253-262

  Macdonald, Nancy ^a   Shapiro, Ari ^a   Bender, Christina ^b   Paolantonio, Marc ^b   Coombs, John ^b  

^a Flince Research + Design   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Compliance; Ethnographic investigation; Gastrointestinal stromal tumors; Imatinib; Medication adherence; Qualitative study

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; BRAZIL; CANADA; CANCER CONTROL; CANCER GROWTH; CANCER SURGERY; CAREGIVER; CLINICAL ARTICLE; ETHNOGRAPHY; EXPERIENCE; FOLLOW UP; FRANCE; GASTROINTESTINAL STROMAL TUMOR; GERMANY; HUMAN; INTERPERSONAL COMMUNICATION; QUALITATIVE RESEARCH; RUSSIAN FEDERATION; SEMI STRUCTURED INTERVIEW; SPAIN; TREATMENT RESPONSE; UNCERTAINTY; UNITED STATES;

EID: 84880128995     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S24617     Document Type: Article

References (19)

1. Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg. 2006;202(4):623-629.
2. Kindblom L-G, Meis-Kindblom J, Bumming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST)-a population-based study of 600 cases. Annals of Oncology Abstract Book of the 27th ESMO Congress; October 18-22, 2002; Nice, France. Ann Oncol. 2002;13(Suppl 5):157.
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438(1):1-12.
4. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626-632.
5. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127-1134.
6. Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010;11(10):942-949.
7. Ray-Coquard IL, Bin Bui N, Adenis A, et al. Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study. J Clin Oncol (Meeting Abstracts). 2010;28(15 Suppl):10032.
8. Joensuu H, Eriksson M, Hatrmann J, et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol. 2011;29(Suppl):LBA1.
9. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51-58.
10. Gleevec/Glivec prescribing information. East Hanover: Novartis Pharmaceuticals Corporation; c2010 [revised 2010 Feb]. http://www. pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf. Accessed January 27, 2011.
11. Clinical practice guidelines in oncology. Soft tissue sarcoma. V.2.2011. Fort Washington: National Comprehensive Cancer Network; c2011. Available at: http://www.nccn.org/professionals/physician_gls/f_-guidelines.asp. Accessed September 10, 2011.
12. Casali PG, Blay JY. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v98-v102.
13. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94(9):652-661.
14. Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J Clin Oncol (Meeting Abstracts). 2006;24(18 Suppl):6119.
15. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620-625.
16. DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097-1104.
17. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472-480.
18. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25(9):1107-1113.
19. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/ metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009; 27(19):3141-3147.